High-dose methotrexate in acute lymphoblastic leukemia: Where is the evidence for its continued use?

Elpis Mantadakis, Peter D. Cole, Barton A. Kamen

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

High-dose intravenous methotrexate is an important component of many effective chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL). Its use has a strong pharmacologic rationale: to overcome mechanisms of resistance of the malignant cells and to achieve cytotoxic concentrations in sanctuary sites for lymphoblasts. Although therapeutic progress in ALL during the past 4 decades has been closely associated with more widespread use of intravenous methotrexate and in progressively larger doses, little data exist to clearly support the use of high-dose intravenous methotrexate over a regimen of prolonged administration of low-dose methotrexate. The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue. The evidence favoring administration of intravenous methotrexate for children with ALL is critically reviewed. Despite its extensive use, high-dose intravenous methotrexate has not been proved conclusively to be more effective than less toxic, less labor intensive, and less costly methods of methotrexate administration.

Original languageEnglish (US)
Pages (from-to)748-755
Number of pages8
JournalPharmacotherapy
Volume25
Issue number5 I
DOIs
StatePublished - May 2005
Externally publishedYes

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Methotrexate
Leucovorin
Poisons
Intravenous Administration

Keywords

  • Acute lymphoblastic leukemia
  • ALL
  • Leucovorin
  • Methotrexate

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

High-dose methotrexate in acute lymphoblastic leukemia : Where is the evidence for its continued use? / Mantadakis, Elpis; Cole, Peter D.; Kamen, Barton A.

In: Pharmacotherapy, Vol. 25, No. 5 I, 05.2005, p. 748-755.

Research output: Contribution to journalArticle

Mantadakis, Elpis ; Cole, Peter D. ; Kamen, Barton A. / High-dose methotrexate in acute lymphoblastic leukemia : Where is the evidence for its continued use?. In: Pharmacotherapy. 2005 ; Vol. 25, No. 5 I. pp. 748-755.
@article{36179b942da1438aa7e75bcdf1ffa99c,
title = "High-dose methotrexate in acute lymphoblastic leukemia: Where is the evidence for its continued use?",
abstract = "High-dose intravenous methotrexate is an important component of many effective chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL). Its use has a strong pharmacologic rationale: to overcome mechanisms of resistance of the malignant cells and to achieve cytotoxic concentrations in sanctuary sites for lymphoblasts. Although therapeutic progress in ALL during the past 4 decades has been closely associated with more widespread use of intravenous methotrexate and in progressively larger doses, little data exist to clearly support the use of high-dose intravenous methotrexate over a regimen of prolonged administration of low-dose methotrexate. The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue. The evidence favoring administration of intravenous methotrexate for children with ALL is critically reviewed. Despite its extensive use, high-dose intravenous methotrexate has not been proved conclusively to be more effective than less toxic, less labor intensive, and less costly methods of methotrexate administration.",
keywords = "Acute lymphoblastic leukemia, ALL, Leucovorin, Methotrexate",
author = "Elpis Mantadakis and Cole, {Peter D.} and Kamen, {Barton A.}",
year = "2005",
month = "5",
doi = "10.1592/phco.25.5.748.63584",
language = "English (US)",
volume = "25",
pages = "748--755",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "5 I",

}

TY - JOUR

T1 - High-dose methotrexate in acute lymphoblastic leukemia

T2 - Where is the evidence for its continued use?

AU - Mantadakis, Elpis

AU - Cole, Peter D.

AU - Kamen, Barton A.

PY - 2005/5

Y1 - 2005/5

N2 - High-dose intravenous methotrexate is an important component of many effective chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL). Its use has a strong pharmacologic rationale: to overcome mechanisms of resistance of the malignant cells and to achieve cytotoxic concentrations in sanctuary sites for lymphoblasts. Although therapeutic progress in ALL during the past 4 decades has been closely associated with more widespread use of intravenous methotrexate and in progressively larger doses, little data exist to clearly support the use of high-dose intravenous methotrexate over a regimen of prolonged administration of low-dose methotrexate. The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue. The evidence favoring administration of intravenous methotrexate for children with ALL is critically reviewed. Despite its extensive use, high-dose intravenous methotrexate has not been proved conclusively to be more effective than less toxic, less labor intensive, and less costly methods of methotrexate administration.

AB - High-dose intravenous methotrexate is an important component of many effective chemotherapeutic regimens for childhood acute lymphoblastic leukemia (ALL). Its use has a strong pharmacologic rationale: to overcome mechanisms of resistance of the malignant cells and to achieve cytotoxic concentrations in sanctuary sites for lymphoblasts. Although therapeutic progress in ALL during the past 4 decades has been closely associated with more widespread use of intravenous methotrexate and in progressively larger doses, little data exist to clearly support the use of high-dose intravenous methotrexate over a regimen of prolonged administration of low-dose methotrexate. The implied superiority of intravenous methotrexate mainly stems from studies that used identical leucovorin rescue with low-dose methotrexate or from studies of upfront window therapy in untreated children with ALL in which single standard doses of oral methotrexate were compared with high-dose intravenous methotrexate with leucovorin rescue. The evidence favoring administration of intravenous methotrexate for children with ALL is critically reviewed. Despite its extensive use, high-dose intravenous methotrexate has not been proved conclusively to be more effective than less toxic, less labor intensive, and less costly methods of methotrexate administration.

KW - Acute lymphoblastic leukemia

KW - ALL

KW - Leucovorin

KW - Methotrexate

UR - http://www.scopus.com/inward/record.url?scp=18044370066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=18044370066&partnerID=8YFLogxK

U2 - 10.1592/phco.25.5.748.63584

DO - 10.1592/phco.25.5.748.63584

M3 - Article

C2 - 15899736

AN - SCOPUS:18044370066

VL - 25

SP - 748

EP - 755

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 5 I

ER -